Loading...
Bienvenue sur la collection HAL du laboratoire de BECCOH
Quelques conseils pour une publication "idéHALe"
• Pensez à respecter la signature institutionnelle
Université Paris-Saclay, UVSQ, BECCOH, 92104, Boulogne-Billancourt, France..
• Participez à l'accès ouvert
N'attendez pas : dès que votre article est en ligne, déposez dans Hal sa version acceptée pour publication et indiquez un embargo de 6 mois.
La loi pour une république numérique vous autorise en effet à partager cette version 6 mois après publications, quelque-soit l'éditeur
Plus d'informations Archives Ouverte : quid de mes droits d'auteurs ?
• Vous souhaitez disposer d'une page web référençant toutes vos publications ?
Créez vous en 5 minutes un idHal et un CVHAL
N'hésitez pas à nous contacter pour toutes questions,
nous serions ravis d'échanger avec vous hal.bib@uvsq.fr
nous serions ravis d'échanger avec vous hal.bib@uvsq.fr
Dernières Publications en accès ouvert dans Hal
-
Paul Takam Kamga, Marie Mayenga, Louise Sebane, Adrien Costantini, Catherine Julie, et al.. Colony stimulating factor-1 (CSF-1) signalling is predictive of response to immune checkpoint inhibitors in advanced non-small cell lung cancer. Lung Cancer, 2024, 188, pp.107447. ⟨10.1016/j.lungcan.2023.107447⟩. ⟨hal-04517531⟩
-
Alexander Stratigos, Claus Garbe, Clio Dessinioti, Celeste Lebbe, Alexander van Akkooi, et al.. European consensus-based interdisciplinary guideline for invasive cutaneous squamous cell carcinoma: Part 2. Treatment–Update 2023. European Journal of Cancer, 2023, 193, pp.113252. ⟨10.1016/j.ejca.2023.113252⟩. ⟨inserm-04209605⟩
-
Alexander Stratigos, Claus Garbe, Clio Dessinioti, Celeste Lebbe, Alexander van Akkooi, et al.. European consensus-based interdisciplinary guideline for invasive cutaneous squamous cell carcinoma. Part 1: Diagnostics and prevention–Update 2023. European Journal of Cancer, 2023, 193, pp.113251. ⟨10.1016/j.ejca.2023.113251⟩. ⟨inserm-04210036⟩
-
Julien Taïeb, Olivier Bouche, Thierry André, Karine Le Malicot, Pierre Laurent-Puig, et al.. Avelumab vs Standard Second-Line Chemotherapy in Patients with Metastatic Colorectal Cancer and Microsatellite Instability: A Randomized Clinical Trial. JAMA oncology, 2023, 9 (10), ⟨10.1001/jamaoncol.2023.2761⟩. ⟨hal-04322943⟩
-
Amandine Desette, Pierre-Olivier Guichet, Sheik Emambux, Konstantin Masliantsev, Ulrich Cortes, et al.. Deciphering Brain Metastasis Stem Cell Properties From Colorectal Cancer Highlights Specific Stemness Signature and Shared Molecular Features. Cellular and Molecular Gastroenterology and Hepatology, 2023, 16 (5), pp.757-782. ⟨10.1016/j.jcmgh.2023.07.008⟩. ⟨hal-04302791⟩
Mots clés
Advanced melanoma
Merkel cell carcinoma
Anti-PD-1 antibody
Anti-CTLA-4 anti-PD-1 elderly immune checkpoint inhibitors melanoma nonagenarian octogenarian
Trametinib
Circulating cell-free DNA
Immunohistochemistry
Chemotherapy
Metastatic cSCC
Non-small cell lung cancer
Bone marrow niche
Survival
TNM classification
Brain Metastases
Adjuvant therapy
Safety
Biliopancreatic diversion
Wnt
Radiofrequency ablation
Adjuvant
Prognostic
Surgical excision
Bariatric surgery
Langerhans cell histiocytosis
Metastatic
Chemoresistance
BRAF V600E
Treatment
Immunotherapy
Melanoma
Body mass index
Advanced
Anti-CTLA-4
EGFR
Molecular targeted therapies
Staging
Anti-PD1
Anti-PD-1
Sonic Hedgehog
Anti-PD1 blockade
Androgen insensitivity
BRAFV600E mutation
Cancer
Plasma
CARMN
Acute generalized exanthematous pustulosis
Resistance
Abscopal effect
ACTH
2-chlorodeoxyadenosine
Systemic therapy
Cemiplimab
Adverse events
Prognosis
BRAFV600E
Circulating tumor DNA
Colorectal cancer
Diagnosis
Antibody-drug conjugate
Cutaneous squamous cell carcinoma
Adapted physical activity molecular diagnosis oligometastatic disease pancreatic adenocarcinoma KRAS mutation
Children
Dabrafenib
Targeted therapy
Colon cancer
Prevention
Histiocytosis
Follow-up
Biomarkers
BRAFV600-mutant melanoma
Invasive cutaneous squamous cell carcinoma
Abscopal effect anti-PD-1 antibody melanoma nivolumab pembrolizumab radiotherapy
Abdominal pain
Mesenchymal stromal cells
BRAF V600-mutation
Locally advanced
AML
Immune checkpoint inhibitor
Cancer bronchique non à petites cellules
C797S
Radiotherapy
BRAF
Beta-catenin
ADN tumoral circulant
Immunomodulation
Biomarker
Anti-Tumor pharmacology
ALK
Gastric bypass
Nivolumab
Polyomavirus
AZD9291
Lung adenocarcinoma
Osimertinib
Colorectal carcinoma
Adjuvant FOLFOX
ALK rearrangement
Allelic imbalance
Antineoplastic agents
Crizotinib